Bristol-Myers Squibb Company (BMY) : Analyst Rating Update

Bristol-Myers Squibb Company (BMY) : The consensus on Bristol-Myers Squibb Company (BMY) based on 17 analyst recommendation on the company stock is 2.32, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 7 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 7 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 2 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.

Bristol-Myers Squibb Company (BMY) : The consensus price target for Bristol-Myers Squibb Company (BMY) is $73.86 for the short term with a standard deviation of $13.47. The most optimist securities analyst among the 14 who monitor the stock believes that the stock can reach $100, however, the pessimist price target for the company is $48.

Bristol-Myers Squibb Company (NYSE:BMY): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $74.01 and $72.87 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $74.06. The buying momentum continued till the end and the stock did not give up its gains. It closed at $73.86, notching a gain of 0.11% for the day. The total traded volume was 6,517,612 . The stock had closed at $73.78 on the previous day.

Also, In the latest statement by the brokerage house, Jefferies maintains its outlook on Bristol-Myers Squibb Company (NYSE:BMY). The current rating of the shares is Hold, according to the research report released by the firm. The brokerage firm raises the price target from $76 per share to $78 per share. The rating by the firm was issued on June 14, 2016. The company shares have rallied 8.92% from its 1 Year high price. On Jun 6, 2016, the shares registered one year high at $75.12 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $72.02 and the 200 Day Moving Average price is recorded at $67.17.

Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *